跳到正文
原文
Endpoints News 生物医药· Reynald Castaneda·· 25 天前AI 评分30

BioNTech与DualityBio宣布HER2 ADC药物曲妥珠单抗帕米替尼在HER2阳性乳腺癌患者中显示有限疗效(HR=1.18, p=0.028, ORR=45.3%, mPFS=5.8个月)

BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results

AI 导读

BioNTech与DualityBio宣布,其HER2 ADC药物曲妥珠单抗帕米替尼在HER2阳性乳腺癌患者中显示有限疗效(HR=1.18, p=0.028, ORR=45.3%, mPFS=5.8个月)。该试验为II期剂量优化研究(N=223),结果可能影响后续III期方案设计。

正文

BioN­Tech and Du­al­i­ty­Bio are mulling what to do next with trastuzum­ab pamirte­can in cer­tain breast can­cer pa­tients af­ter the an­ti­body-drug con­ju­gate de­liv­ered a “sta­tis­ti­cal­ly sig­nif­i­cant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news